Table 5. Sensitivity analysis.
Model-projected percentage of vaccinees at the end of the pandemic who were infected with A/H1N1 2009 pandemic influenza virus before receiving vaccination in Norway, by age, for each of the scenarios tested.
| Percentage of vaccinees infected with A/H1N1 2009 pandemic influenza virus before receiving A/H1N1 2009 pandemic influenza virus vaccination | ||||||
|---|---|---|---|---|---|---|
| Age group (years) | Base case (Scenario 1) | Scenario 2a | Scenario 3 a | Scenario 4 a | Scenario 5 a | Immune at start * |
| 0–<10 | 62% | 74% | 100% | 60% | 32% | 0% |
| 10–<20 | 66% | 76% | 96% | 65% | 45% | 0% |
| 20–<30 | 59% | 84% | 100% | 57% | 45% | 0% |
| 30–<50 | 63% | 82% | 90% | 62% | 54% | 0% |
| 50+ | 44% | 51% | 55% | 43% | 39% | 12% |
| 50-<65** | 48% | 59% | 65% | 47% | 41% | 5% |
| 65+** | 38% | 42% | 43% | 38% | 35% | 21% |
| All | 56% | 69% | 81% | 55% | 43% | 4% |
a See definition of the four scenarios in the Materials and Methods section.
*age-group-specific percentage assumed immune at start of the H1N1 epidemic.
** outcome in the 50+ are also presented splited 50-<65 and 65+